Celerion Acquires Early Stage Clinical Research Operations from MDS Pharma Services
Celerion, a privately owned contract research organization (CRO), has completed the acquisition of the development and regulatory services consultancy and early stage development operations of MDS Pharma Services. The acquired assets include five clinical research facilities and two bioanalytical laboratories located in Lincoln, Nebraska; Neptune, New Jersey; Phoenix, Arizona; Zurich, Switzerland; and Belfast, Northern Ireland, as well as operations in Richmond, Virginia and Quebec, Canada.
Life sciences and CRO industry veteran Susan Thornton, Ph.D., is Chief Executive Officer of Celerion. “I'm energized by the prospect of taking this great business to the next level of market leadership,” she said. “We look forward to continuing to provide our pharmaceutical, biotechnology and generic clients with early stage clinical research services. Like the company I am leading, my roots are in MDS Pharma Services.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
